CPPs, as an important active ingredient and biomarker of CP(Luan et al., 2021; Yue et al., 2023), play important pharmacological roles in a wide range of diseases, especially metabolic diseases (Zhang Y. et al., 2020; Bai et al., 2022; Chen S. et al., 2024), digestive diseases (Meng et al., 2020; Zhou et al., 2024), hepatic diseases (Hu et al., 2022; Meng X. et al., 2023), neurological diseases (Wan et al., 2020; Hu et al., 2021) and respiratory diseases (Gong et al., 2022). This evidence concerns the gene CP and nervous system disorder.